

Personalis

Introduction to Personalis

Revolutionizing Cancer Management with Early Recurrence Detection and Personalized Therapies

August 2026

© 2026 Personalis, Inc. All rights reserved. All trademarks are the property of Personalis, Inc. or their respective owners. All products described here are for Research Use Only and not for use in diagnostic procedures (except as specifically noted).

Forward-Looking Statements

This presentation contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements and implied expectations or results other than statements of historical fact contained in this presentation, including statements as to business strategy, plans, and objectives of management for future operations of Personalis, Inc. ("Personalis" or the "Company"), future market sizes, potential success of personalized cancer therapies and other drugs, performance and sensitivity of NeXT Personal and competing cancer detection offerings, the anticipated benefits of obtaining Medicare reimbursement for the NeXT Personal Dx test, the strength of the Company's intellectual property portfolio, and others, are forward-looking statements. These statements involve known and unknown risks, uncertainties, assumptions and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the Company's business in general, please refer to Personalis' filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026, and any current and periodic reports filed thereafter and in the documents incorporated by reference therein.

In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would," or the negative of these words or other similar terms or expressions. These statements are only predictions. Personalis has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Such forward-looking statements and implied expectations involve known and unknown risks and uncertainties and other factors that may cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements, including the risks, uncertainties and other factors that relate to the pending acquisition by Tempus AI, Inc. ("Tempus"), including the occurrence of any event, change or other circumstances that could give rise to the termination of the agreement and plan of merger (the "Agreement"), the possibility that Personalis shareholders may not adopt the Agreement, the risk that Personalis or Tempus may be unable to obtain governmental and regulatory approvals and clearances required for the proposed transaction, or required governmental and regulatory approvals and clearances may delay the transaction or result in the imposition of conditions that could cause the parties to abandon the transaction, the risk that the parties may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all, risks related to disruption of management time from ongoing business operations due to the proposed transaction, the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Personalis' common stock. Also, these forward-looking statements represent the Company's estimates and assumptions only as of the date of this presentation. The Company assumes no obligation to update any forward-looking statements after the date of this presentation, except as required by law.

This presentation also contains estimates and information concerning the Company's industry and business, including estimated market size and projected growth rates of the markets in which Personalis participates. These data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company has not independently verified the statistical and other industry data generated by independent parties and contained in this presentation and, accordingly, cannot guarantee their accuracy or completeness. In addition, projections, assumptions and estimates of its future performance and the future performance of the industries in which the Company operates are necessarily subject to a high degree of uncertainty and risk due to a variety of factors. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by Personalis.


The trademarks included in this presentation are the property of the owners thereof and are used for reference purposes only.

The Future of Cancer Management is Here

Cancer treatment has improved, but today's "best practices" fall short in two critical ways.



Our patented innovations **redefine best practices** that will transform lives.



OUR VISION

Cancer care that harnesses the **unique biology** of each patient to detect cancer **earlier** and treat it more effectively.

Our Technology Led to the Launch of Four Industry Leading Products

Advanced Tumor Profiling



ImmunoID NeXT®

Optimizing patient selection for drug trials

Precise Genetic Analysis



NeXT Dx®

Revealing the unique genetic signatures of solid tumors

Personalized Cancer Therapies



ImmunoID NeXT®

Enabling biotech partners to develop personalized cancer therapies

Early Recurrence Detection



NeXT Personal® Dx

Detecting cancer recurrence significantly earlier than standard methods

Those Products Fuel a Growing Business

Increasing Clinical Test Volume

37,000+ Tests

Delivered 10,384 clinical tests in Q2-2026 and more than 37,000 tests to date

More than 1,400 ordering physicians in Q2-2026

Growing Test Volume

+

Medicare Reimbursement

=

High-Growth Engine

*Clinical revenue for Q2-2026 grew **442%** to **$2.6** million year-over-year*

We Know the Medicare Process

Medicare

NeXT Personal Dx (MRD[1]) is **approved** for Medicare reimbursement of 4 indications including breast, lung, and IO monitoring

NeXT Dx (CGP[2]) is also **approved** for Medicare reimbursement

1. MRD: minimal residual disease test
2. CGP: comprehensive genomic profiling test

Our Technology Has Robust Legal Protection

More than **70** patents world-wide

US



38
Patents

Personalis | Myriad genetics

2024 Myriad agreement provides non-exclusive access to all Myriad IP for cancer recurrence blood testing, strengthening our market position



Early Detection Matters

Patients face agonizing uncertainty about cancer recurrence.

Personalis offers answers sooner.

- Is my cancer gone?
- Do I need different therapies?
- Will we catch it in time if it returns?

Introducing

NeXT Personal® Dx

Clinically available “ultra-sensitive” test that detects tiny tumor pieces in the blood, **earlier than ever before**.



Tumors shed **tiny pieces of cancer DNA** into the blood.



NeXT Personal Dx can **reliably detect tiny DNA fragments with a blood test**



Healthcare providers can **act earlier**, when it matters most.

NeXT Personal Dx Provides “1-in-a-Million” Personalized Cancer Detection



We **analyze each patient’s** solid tumor.

We **identify** up to ~1800 unique DNA markers present in the tumor but not healthy blood.

NeXT Personal Dx detects even **1 cancerous tumor fragment in a million** normal cells with a simple sample



Can Help doctors:

- See if treatment is working.
- Know if more/different treatment may be needed.
- Monitor risk of recurrence.

What NeXT Personal Dx Means for Patients and Physicians

Periodic imaging requires **longer waits** for answers.




While Imaging is vital, it often detects recurrence later than desired.



Patients with solid tumors wait months for periodic imaging like CT, PET, and MRI to know if their cancer returned.

NeXT Personal Dx



NeXT Personal Dx blood tests offer patients and doctors an **easy, reliable way to detect cancer recurrence up to 5 years earlier than imaging**, enabling timely, informed treatment decisions.

Strong Clinical Evidence for NeXT Personal Dx

NeXT Personal Dx consistently detects cancer recurrence and progression earlier than scans



Colorectal Cancers

6 months earlier*





Lung Cancers

5 months earlier*





Breast Cancers

15 months earlier*





Cervical Cancers

5 months earlier*



*Approximate Median Lead Time Ahead of Imaging Scans

2026: Marketplace Success - Accelerating NeXT Personal Growth



Focused Evidence Expansion

Expanding clinical evidence: Studies in breast, colorectal and lung cancer, and immunotherapy monitoring.



Business Catalysts

Additional Medicare coverage drives future revenue growth and gross margin expansion.



Clinical Data Updates

Ultrasensitive MRD Publications in top journals and rapidly expanding studies with oncology leaders and Pharmaceutical partners




Marketplace Adoption

Rapidly increasing volume of testing data drives awareness of NeXT Personal.

Driving Clinical Test Volume Growth with MRD

Includes all molecular tests (NeXT Personal Dx & NeXT Dx)



"Win-in-MRD" with high growth

33% Q2 Sequential quarter growth

10,384 Q2 test volume

>37,000 Tests delivered to date

Proven Leadership with Heritage of Success



Christopher Hall

Chief Executive Officer

Over 20 years experience building life sciences companies and bringing products to market.

Previous experience: CEO of Naring Health,, President, COO, and Chief Commercial Officer at Veracyte.



Karin Eastham

Board Chair

Over 35 years of experience guiding financial and operations management in life sciences companies. Currently sits on Veracyte Board of Directors.

Previous experience: Board member of Nektar Therapeutics, Geron, Illumina, MorphoSys AG, and Amylin. COO of the Burnham Institute for Medical Research and VP, Boehringer Mannheim Diagnostics (now Roche)



Richard Chen, MD

President, Chief Medical Officer

Physician-scientist with over 20 years experience in building innovative genomics and life science companies

Previous experience: Co-founder board member Ingenuity Systems



Aaron Tachibana

Chief Financial Officer

Over 25 years experience in executive financial management scaling high-growth public and private companies.

Previous experience: Lumentum, JDS Uniphase, Pericom Semiconductor.



Stephen Moore, JD

Senior Vice President, Chief Legal Officer

Over 20 years experience as in-house legal counsel for advanced genomics companies.

Previous experience: Pacific Biosciences, Navigenics, Affymetrix

Strategic Investment from Industry Leaders Anchor Our Business



Strong Cash Position and No Significant Debt



$22.4MM

Revenue for Q2-2026



~$213MM

Cash balance at Jun 30, 2026; no significant debt